Cost-effective osteoporosis treatment thresholds in Greece

Osteoporosis International

Volumn 26, Issue 7, 2015, Pages 1949-1957

  Makras, P ^a   Athanasakis, K ^b   Boubouchairopoulou, N ^b   Rizou, S ^c   Anastasilakis, A D ^d   Kyriopoulos, J ^b   Lyritis, G P ^c  

^a IASO GENERAL HOSPITAL   (Greece)

^b NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

^c Hellenic Osteoporosis Foundation   (Greece)

^d 424 General Army Hospital   (Greece)

Author keywords

FRAX; Greece; Intervention thresholds; Osteoporosis; Ten year fracture probability

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; BAZEDOXIFENE; CALCIUM; COLECALCIFEROL; DENOSUMAB; IBANDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; VITAMIN D; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; FOREARM FRACTURE; FRACTURE REDUCTION; FRAGILITY FRACTURE; GREECE; HIP FRACTURE; HORMONAL THERAPY; HUMAN; INCIDENCE; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NURSING HOME; OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR; SEX DIFFERENCE; SPINE FRACTURE; VERY ELDERLY; VITAMIN SUPPLEMENTATION; AGE; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE COST; HIP FRACTURES; OSTEOPOROTIC FRACTURES; PROCEDURES; RISK ASSESSMENT; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

AGE FACTORS; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; GREECE; HEALTH CARE COSTS; HIP FRACTURES; HUMANS; MALE; MIDDLE AGED; MODELS, ECONOMETRIC; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; RISK ASSESSMENT; SEX FACTORS;

EID: 84933277800     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-015-3055-8     Document Type: Article

References (30)

1. Majumdar SR (2011) A T-2 translational research perspective on interventions to improve post-fracture osteoporosis care. Osteoporos Int 22(Suppl 3):471–476
2. Lyritis GP, Rizou S, Galanos A, Makras P (2013) Incidence of hip fractures in Greece during a 30-year period: 1977-2007. Osteoporos Int 24:1579–1585
3. Svedbom A, Hernlund E, Ivergard M et al (2013) Epidemiology and economic burden of osteoporosis in Greece. Arch Osteoporos 8:83–90
4. Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, Berger ML, Santora AC, Sherwood LM (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 286:2815–2822
5. Kanis JA, Johnell O, Oden A, Jonsson B, De Laet C, Dawson A (2000) Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone 27:585–590
6. Makras P, Vaiopoulos G, Lyritis GP, Greek National Medicine A (2012) 2011 guidelines for the diagnosis and treatment of osteoporosis in Greece. J Musculoskelet Neuronal Interact 12:38–42
7. Compston J, Cooper A, Cooper C et al (2009) Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 62:105–108
8. Badurski JE, Kanis JA, Johansson H, Dobrenko A, Nowak NA, Daniluk S, Jezienicka E (2011) The application of FRAX(R) to determine intervention thresholds in osteoporosis treatment in Poland. Pol Arch Med Wewn 121:148–155
9. Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, Lindsay RL, National Osteoporosis Foundation Guide C (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19:437–447
10. Fujiwara S (2008) Daily practice using guidelines for prevention and treatment of osteoporosis. Risk factors for fracture and guideline for prevention of fracture. Clin Calcium 18:1079–1083
11. Grossman JM, Gordon R, Ranganath VK et al (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 62:1515–1526
12. Lippuner K, Johansson H, Kanis JA, Rizzoli R (2010) FRAX assessment of osteoporotic fracture probability in Switzerland. Osteoporos Int 21:381–389
13. Papaioannou A, Morin S, Cheung AM et al (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182:1864–1873
14. Dawson-Hughes B, National Osteoporosis Foundation Guide C (2008) A revised clinician’s guide to the prevention and treatment of osteoporosis. J Clin Endocrinol Metab 93:2463–2465
15. Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A, National Osteoporosis Guideline G (2008) Case finding for the management of osteoporosis with FRAX—assessment and intervention thresholds for the UK. Osteoporos Int 19:1395–1408
16. Lippuner K, Johansson H, Borgstrom F, Kanis JA, Rizzoli R (2012) Cost-effective intervention thresholds against osteoporotic fractures based on FRAX(R) in Switzerland. Osteoporos Int 23:2579–2589
17. National Osteoporosis Foundation (NOF) (2010) The clinician’s guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation. www.nof.org, Washington, DC
18. Zethraeus N, Borgstrom F, Strom O, Kanis JA, Jonsson B (2007) Cost-effectiveness of the treatment and prevention of osteoporosis—a review of the literature and a reference model. Osteoporos Int 18:9–23
19. WHO Fracture Risk Assessment Tool. http://www.shef.ac.uk/FRAX/?lang=en (Accessed 20th June 2014)
20. Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB, Force I-SMGRPT (2012) Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force—7. Value Health 15:843–850
21. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22:465–475
22. Poor G, Atkinson EJ, O’Fallon WM, Melton LJ, 3rd (1995) Determinants of reduced survival following hip fractures in men. Clin Orthop Relat Res 319:260–265
23. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B (2004) Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 15:108–112
24. Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136
25. National Organization For Health Care Services Provision (NOHCSP). http://www.eopyy.gov.gr/Home/StartPage?a_HomePage=Index (site in Greek). (Accessed 30th March 2014)
26. Hellenic Association of Pharmaceutical Companies (HAPC). http://www.sfee.gr/en/medicine-prices (Accessed 3rd April 2014)
27. National Organization For Health Care Services Provision (NOHCSP). Availableat http://www.eof.gr/web/guest/home; (site in Greek) (Accessed 15th May 2014)
28. European Commission Economic and Financial Affairs. Available at http://ec.europa.eu/economy_finance/ameco/user/serie/ResultSerie.cfm (Accessed 4th October 2014)
29. Strom O, Borgstrom F, Kleman M, McCloskey E, Oden A, Johansson H, Kanis JA (2010) FRAX and its applications in health economics—cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example. Bone 47:430–437
30. Strom O, Jonsson B, Kanis JA (2013) Intervention thresholds for denosumab in the UK using a FRAX(R)-based cost-effectiveness analysis. Osteoporos Int 24:1491–1502